41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
Matteo Libero BaroniDiego Sanchez MartinezFrancisco Gutierrez AgueraHeleia Roca HoMaria CastellaSamanta Romina ZanettiTalía Velasco-HernandezRafael Diaz de la GuardiaJulio CastañoEduardo AnguitaSusana VivesJosep NomdedeuHelene LapilloneAnne E BrasVincent H J van der VeldenJordi JuncaPedro MarinAlex BatallerJordi EsteveBinje VickIrmela JeremiasAngel LopezMarc SorigueClara BuenoPablo MenendezPublished in: Journal for immunotherapy of cancer (2021)
This study calls for caution when clinically implementing CD123 CARTs, encouraging its preferential use as a bridge to allo-HSCT in patients with R/R AML.